,address1,city,state,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationMean,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,9708 Medical Center Drive,Rockville,MD,20850,United States,240 243 1201,301 738 2137,https://www.glycomimetics.com,Biotechnology,Healthcare,"GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.",38,"{'maxAge': 1, 'name': 'Mr. Harout  Semerjian', 'age': 52, 'title': 'CEO, Pres & Director', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 1096122, 'exercisedValue': 0, 'unexercisedValue': 366134}",7,6,8,8,7,1693526400,1672444800,86400,4,1.47,1.46,1.41,1.5,1.47,1.46,1.41,1.5,0.0,2.044605,-2.3114753,156645,156645,117596,100820,100820,1.42,1.6,800,1400,90685984,0.55,4.16,Infinity,1.6,1.9066,0.0,0.0,USD,37776860,0.0,39557077,64316300,1036884,1160146,1690761600,1693440000,0.0161,0.02678,0.58248,9.88,0.0232,0.852,1.6549295,1672444800,1703980800,1688083200,-37386456,-0.66,-0.61,-0.967,NGM,EQUITY,GLYC,GLYC,"GlycoMimetics, Inc.","GlycoMimetics, Inc.",1389364200,America/New_York,EDT,-14400000,1.41,1.7,buy,58037072,0.902,-39080696,1269018,8.864,9.186,0,2.316,0.0,-0.38684,-0.6765,75000,-24273952,-35110396,0.0,0.0,0.0,USD,
1,9708 Medical Center Drive,Rockville,MD,20850,United States,240 243 1201,301 738 2137,https://www.glycomimetics.com,Biotechnology,Healthcare,"GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.",38,"{'maxAge': 1, 'name': 'Ms. Rachel K. King', 'age': 63, 'title': 'Co-Founder & Director', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 226433, 'exercisedValue': 0, 'unexercisedValue': 0}",7,6,8,8,7,1693526400,1672444800,86400,4,1.47,1.46,1.41,1.5,1.47,1.46,1.41,1.5,0.0,2.044605,-2.3114753,156645,156645,117596,100820,100820,1.42,1.6,800,1400,90685984,0.55,4.16,Infinity,1.6,1.9066,0.0,0.0,USD,37776860,0.0,39557077,64316300,1036884,1160146,1690761600,1693440000,0.0161,0.02678,0.58248,9.88,0.0232,0.852,1.6549295,1672444800,1703980800,1688083200,-37386456,-0.66,-0.61,-0.967,NGM,EQUITY,GLYC,GLYC,"GlycoMimetics, Inc.","GlycoMimetics, Inc.",1389364200,America/New_York,EDT,-14400000,1.41,1.7,buy,58037072,0.902,-39080696,1269018,8.864,9.186,0,2.316,0.0,-0.38684,-0.6765,75000,-24273952,-35110396,0.0,0.0,0.0,USD,
2,9708 Medical Center Drive,Rockville,MD,20850,United States,240 243 1201,301 738 2137,https://www.glycomimetics.com,Biotechnology,Healthcare,"GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.",38,"{'maxAge': 1, 'name': 'Mr. Brian M. Hahn', 'age': 48, 'title': 'Sr. VP & CFO', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 748271, 'exercisedValue': 0, 'unexercisedValue': 0}",7,6,8,8,7,1693526400,1672444800,86400,4,1.47,1.46,1.41,1.5,1.47,1.46,1.41,1.5,0.0,2.044605,-2.3114753,156645,156645,117596,100820,100820,1.42,1.6,800,1400,90685984,0.55,4.16,Infinity,1.6,1.9066,0.0,0.0,USD,37776860,0.0,39557077,64316300,1036884,1160146,1690761600,1693440000,0.0161,0.02678,0.58248,9.88,0.0232,0.852,1.6549295,1672444800,1703980800,1688083200,-37386456,-0.66,-0.61,-0.967,NGM,EQUITY,GLYC,GLYC,"GlycoMimetics, Inc.","GlycoMimetics, Inc.",1389364200,America/New_York,EDT,-14400000,1.41,1.7,buy,58037072,0.902,-39080696,1269018,8.864,9.186,0,2.316,0.0,-0.38684,-0.6765,75000,-24273952,-35110396,0.0,0.0,0.0,USD,
3,9708 Medical Center Drive,Rockville,MD,20850,United States,240 243 1201,301 738 2137,https://www.glycomimetics.com,Biotechnology,Healthcare,"GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.",38,"{'maxAge': 1, 'name': 'Ms. Stephanie R. Irish CPA', 'age': 51, 'title': 'VP of Accounting', 'yearBorn': 1971, 'exercisedValue': 0, 'unexercisedValue': 0}",7,6,8,8,7,1693526400,1672444800,86400,4,1.47,1.46,1.41,1.5,1.47,1.46,1.41,1.5,0.0,2.044605,-2.3114753,156645,156645,117596,100820,100820,1.42,1.6,800,1400,90685984,0.55,4.16,Infinity,1.6,1.9066,0.0,0.0,USD,37776860,0.0,39557077,64316300,1036884,1160146,1690761600,1693440000,0.0161,0.02678,0.58248,9.88,0.0232,0.852,1.6549295,1672444800,1703980800,1688083200,-37386456,-0.66,-0.61,-0.967,NGM,EQUITY,GLYC,GLYC,"GlycoMimetics, Inc.","GlycoMimetics, Inc.",1389364200,America/New_York,EDT,-14400000,1.41,1.7,buy,58037072,0.902,-39080696,1269018,8.864,9.186,0,2.316,0.0,-0.38684,-0.6765,75000,-24273952,-35110396,0.0,0.0,0.0,USD,
4,9708 Medical Center Drive,Rockville,MD,20850,United States,240 243 1201,301 738 2137,https://www.glycomimetics.com,Biotechnology,Healthcare,"GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.",38,"{'maxAge': 1, 'name': 'Mr. Christian B. Dinneen-Long', 'title': 'Gen. Counsel & Company Sec.', 'exercisedValue': 0, 'unexercisedValue': 0}",7,6,8,8,7,1693526400,1672444800,86400,4,1.47,1.46,1.41,1.5,1.47,1.46,1.41,1.5,0.0,2.044605,-2.3114753,156645,156645,117596,100820,100820,1.42,1.6,800,1400,90685984,0.55,4.16,Infinity,1.6,1.9066,0.0,0.0,USD,37776860,0.0,39557077,64316300,1036884,1160146,1690761600,1693440000,0.0161,0.02678,0.58248,9.88,0.0232,0.852,1.6549295,1672444800,1703980800,1688083200,-37386456,-0.66,-0.61,-0.967,NGM,EQUITY,GLYC,GLYC,"GlycoMimetics, Inc.","GlycoMimetics, Inc.",1389364200,America/New_York,EDT,-14400000,1.41,1.7,buy,58037072,0.902,-39080696,1269018,8.864,9.186,0,2.316,0.0,-0.38684,-0.6765,75000,-24273952,-35110396,0.0,0.0,0.0,USD,
5,9708 Medical Center Drive,Rockville,MD,20850,United States,240 243 1201,301 738 2137,https://www.glycomimetics.com,Biotechnology,Healthcare,"GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.",38,"{'maxAge': 1, 'name': 'Mr. Bruce  Johnson', 'age': 54, 'title': 'Sr. VP & Chief Commercial Officer', 'yearBorn': 1968, 'exercisedValue': 0, 'unexercisedValue': 0}",7,6,8,8,7,1693526400,1672444800,86400,4,1.47,1.46,1.41,1.5,1.47,1.46,1.41,1.5,0.0,2.044605,-2.3114753,156645,156645,117596,100820,100820,1.42,1.6,800,1400,90685984,0.55,4.16,Infinity,1.6,1.9066,0.0,0.0,USD,37776860,0.0,39557077,64316300,1036884,1160146,1690761600,1693440000,0.0161,0.02678,0.58248,9.88,0.0232,0.852,1.6549295,1672444800,1703980800,1688083200,-37386456,-0.66,-0.61,-0.967,NGM,EQUITY,GLYC,GLYC,"GlycoMimetics, Inc.","GlycoMimetics, Inc.",1389364200,America/New_York,EDT,-14400000,1.41,1.7,buy,58037072,0.902,-39080696,1269018,8.864,9.186,0,2.316,0.0,-0.38684,-0.6765,75000,-24273952,-35110396,0.0,0.0,0.0,USD,
6,9708 Medical Center Drive,Rockville,MD,20850,United States,240 243 1201,301 738 2137,https://www.glycomimetics.com,Biotechnology,Healthcare,"GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.",38,"{'maxAge': 1, 'name': 'Dr. Edwin  Rock M.D., Ph.D.', 'age': 61, 'title': 'Sr. VP & Chief Medical Officer', 'yearBorn': 1961, 'exercisedValue': 0, 'unexercisedValue': 0}",7,6,8,8,7,1693526400,1672444800,86400,4,1.47,1.46,1.41,1.5,1.47,1.46,1.41,1.5,0.0,2.044605,-2.3114753,156645,156645,117596,100820,100820,1.42,1.6,800,1400,90685984,0.55,4.16,Infinity,1.6,1.9066,0.0,0.0,USD,37776860,0.0,39557077,64316300,1036884,1160146,1690761600,1693440000,0.0161,0.02678,0.58248,9.88,0.0232,0.852,1.6549295,1672444800,1703980800,1688083200,-37386456,-0.66,-0.61,-0.967,NGM,EQUITY,GLYC,GLYC,"GlycoMimetics, Inc.","GlycoMimetics, Inc.",1389364200,America/New_York,EDT,-14400000,1.41,1.7,buy,58037072,0.902,-39080696,1269018,8.864,9.186,0,2.316,0.0,-0.38684,-0.6765,75000,-24273952,-35110396,0.0,0.0,0.0,USD,
7,9708 Medical Center Drive,Rockville,MD,20850,United States,240 243 1201,301 738 2137,https://www.glycomimetics.com,Biotechnology,Healthcare,"GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.",38,"{'maxAge': 1, 'name': 'Mr. Chinmaya  Rath', 'age': 46, 'title': 'Sr. VP & Chief Bus. Officer', 'yearBorn': 1976, 'exercisedValue': 0, 'unexercisedValue': 0}",7,6,8,8,7,1693526400,1672444800,86400,4,1.47,1.46,1.41,1.5,1.47,1.46,1.41,1.5,0.0,2.044605,-2.3114753,156645,156645,117596,100820,100820,1.42,1.6,800,1400,90685984,0.55,4.16,Infinity,1.6,1.9066,0.0,0.0,USD,37776860,0.0,39557077,64316300,1036884,1160146,1690761600,1693440000,0.0161,0.02678,0.58248,9.88,0.0232,0.852,1.6549295,1672444800,1703980800,1688083200,-37386456,-0.66,-0.61,-0.967,NGM,EQUITY,GLYC,GLYC,"GlycoMimetics, Inc.","GlycoMimetics, Inc.",1389364200,America/New_York,EDT,-14400000,1.41,1.7,buy,58037072,0.902,-39080696,1269018,8.864,9.186,0,2.316,0.0,-0.38684,-0.6765,75000,-24273952,-35110396,0.0,0.0,0.0,USD,
